BioTuesdays

Tag - Cantor Fitzgerald

vTv Therapeutics Logo
Markets

Cantor starts vTv at OW; PT $5

Cantor Fitzgerald launched coverage of vTv Therapeutics (NASDAQ:VTVT) with an “overweight” rating and 12-month price target of $5. The stock closed at 71 cents on Feb. 17. vTv is developing novel orally administered...

February 18, 2022
oramed
Markets

Cantor starts Oramed at OW; PT $20

Cantor Fitzgerald launched coverage of Oramed Pharmaceuticals (NASDAQ:ORMP) with an “overweight” rating and price target of $20. The stock closed at $10.63 on Feb. 17. Oramed is a developing novel drug formulations for...

February 18, 2022
Collegium Pharma
Markets

Cantor ups Collegium Pharma to OW; PT to $26 from $17

Cantor Fitzgerald upgraded Collegium Pharmaceuticals (NASDAQ:COLL) to “overweight” from “neutral” and raised its price target to $26 from $17, citing its agreement to acquire BioDelivery Sciences International.  Shares...

February 14, 2022
Bionomics
Markets

Analysts start Bionomics at OW, OP

Analysts for Cantor Fitzgerald and William Blair launched coverage of Bionomics (NASDAQ:BNOX) with “overweight” and “outperform” ratings, respectively. Australia-based Bionomics is a clinical-stage biopharmaceutical...

January 10, 2022
Vincerx Logo
Markets

Cantor starts Vincerx Pharma at OW; PT $25

Cantor Fitzgerald initiated coverage of Vincerx Pharma (NASDAQ:VINC) with an “overweight” rating and $25 price target. The stock closed at $10.30 on Dec. 22. Vincerx is a clinical-stage oncology company that is on track...

December 23, 2021
Cardiol Therapeutics
Markets

Cantor starts Cardiol at OW; PT $8

Cantor Fitzgerald launched coverage of Cardiol Therapeutics (NASDAQ:CRDL) with an “overweight” rating and price target of $8. The stock closed at $1.87 on Dec. 16. Cardiol is a clinical-stage, platform-enabled...

December 17, 2021
AcelRx Pharma Logo
Markets

Cantor cuts AcelRx PT to $4 from $9; maintains OW

Cantor Fitzgerald reduced its price target for AcelRx Pharmaceuticals (NASDAQ:ACX) to $4 from $9, but maintained its “overweight” rating, citing a revised ramp in Dsuvia sales, as well as recent acquisitions and an...

December 2, 2021
Annexon Biosciences New
Markets

Cantor starts Annexon at OW; PT $40

Cantor Fitzgerald initiated coverage of Annexon (NASDAQ:ANNX) with an “overweight” rating and $40 price target. The stock closed at $21.12 on Sept. 22. Annexon is a platform-enabled therapeutics company focused on...

September 23, 2021